The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Platelet levels above 250,000/μL prior to surgery for high-risk renal cell carcinoma are independently associated with a 1.5-fold increase risk for recurrence.
Positive surgical margins in patients undergoing partial nephrectomy for cT1b renal cell carcinoma are associated with worse 5-year recurrence-free and overall survival.
Elevated C-reactive protein levels prior to nephrectomy for renal cell carcinoma is associated with an increased risk of renal impairment, a study found.
In a study, left-sided renal cell carcinoma (RCC) was associated with a 16% to 19% increased risk of dying from the malignancy compared with right-sided RCC.
In the contemporary era of more effective systemic therapies, complete surgical resection of RCC metastases is associated with improved survival, new findings suggest.
Delaying surgery more than 10 weeks after diagnosis of pT3 renal cell carcinoma is associated with increased 5-year mortality risk.
Study of patients on active surveillance for renal cell carcinoma showed spontaneous tumor regression occurred more often among those with papillary or chromophobe than clear-cell histology.
FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
